The cost-of-living adjustment can’t keep up with the actual cost of living, as retirees’ costs climb.
Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease
Novo Nordisk, the Danish drugmaker behind Ozempic and other weight-loss drugs, said it’s paying up to $5.2 billion to buy Akero Therapeutics,…